Walleye Capital LLC Makes New Investment in BioAtla, Inc. (NASDAQ:BCAB)

Walleye Capital LLC purchased a new stake in BioAtla, Inc. (NASDAQ:BCABGet Rating) in the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 170,326 shares of the company’s stock, valued at approximately $852,000. Walleye Capital LLC owned 0.46% of BioAtla as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Los Angeles Capital Management LLC bought a new position in shares of BioAtla during the first quarter valued at approximately $333,000. Woodline Partners LP increased its position in BioAtla by 196.1% in the fourth quarter. Woodline Partners LP now owns 446,141 shares of the company’s stock worth $8,758,000 after buying an additional 295,446 shares during the period. Twin Lakes Capital Management LLC bought a new stake in BioAtla in the first quarter valued at $45,000. Russell Investments Group Ltd. acquired a new position in shares of BioAtla during the first quarter valued at $286,000. Finally, SG Americas Securities LLC increased its holdings in shares of BioAtla by 165.0% in the 1st quarter. SG Americas Securities LLC now owns 13,524 shares of the company’s stock worth $68,000 after acquiring an additional 8,421 shares during the period. Institutional investors own 69.14% of the company’s stock.

BioAtla Price Performance

NASDAQ BCAB opened at $8.33 on Tuesday. BioAtla, Inc. has a 12 month low of $2.01 and a 12 month high of $34.29. The firm has a market capitalization of $311.66 million, a PE ratio of -3.05 and a beta of -0.12. The company’s 50 day simple moving average is $6.66 and its 200 day simple moving average is $4.71.

BioAtla (NASDAQ:BCABGet Rating) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.07). During the same period in the prior year, the company earned ($0.90) earnings per share. Sell-side analysts anticipate that BioAtla, Inc. will post -3.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BCAB has been the topic of a number of recent analyst reports. JMP Securities assumed coverage on BioAtla in a report on Thursday, September 15th. They set an “outperform” rating and a $17.00 price target on the stock. HC Wainwright decreased their price target on BioAtla from $25.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, August 10th.

Insiders Place Their Bets

In other BioAtla news, CEO Jay M. Phd Short acquired 26,350 shares of the stock in a transaction dated Friday, August 12th. The shares were bought at an average price of $7.84 per share, with a total value of $206,584.00. Following the purchase, the chief executive officer now directly owns 1,396,556 shares of the company’s stock, valued at approximately $10,948,999.04. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 14.80% of the stock is owned by company insiders.

About BioAtla

(Get Rating)

BioAtla, Inc, a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.

Read More

Want to see what other hedge funds are holding BCAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioAtla, Inc. (NASDAQ:BCABGet Rating).

Institutional Ownership by Quarter for BioAtla (NASDAQ:BCAB)

Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.